Navigation Links
Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference

CARLSBAD, Calif., Sept. 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Conference on Monday, September 8, 2014 at 12:50 p.m. ET in New York, NY.

A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website,  A replay will be available on the Isis website within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO®, in the United States and other countries for the treatment of patients with homozygous FH.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at

Forward-Looking Statements
This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2013, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO® is a registered trademark of Genzyme Corporation.

Logo -

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. RXi Pharmaceuticals to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
2. Edison Pharmaceuticals Announces Phase 2 Positive Clinical Results for EPI-743 in Rett Syndrome
3. Avanir Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
4. VentiRx Pharmaceuticals Provides Corporate and Clinical Update
5. Arena Pharmaceuticals APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension
6. VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer
7. DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments
8. CAIDE Looks into the Future: New App from Merz Pharmaceuticals Assesses the Risk of Getting Dementia Within the Next 20 Years
9. Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytrens Cords At ASSH Annual Meeting
10. TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension
11. DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference
Post Your Comments:
(Date:11/25/2015)... 2015 Research and Markets ( ) ... - Global Forecast to 2020" report to their ... for 37.21% of the total market share in 2014. ... region is projected to growth at the highest CAGR ... primarily to the fast growing water, industrial gas treatment, ...
(Date:11/24/2015)... 25, 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" ... open-access R&D capability and technology platform company serving the ... China and the ... extraordinary general meeting of shareholders held today, the Company,s ... and approve the previously announced agreement and plan of ...
(Date:11/24/2015)... N.C. , Nov. 24, 2015  In the ... projects in an effort to quickly uncover new insights, ... --> --> However, ... a market research project and ensure that all rules ... and industry standards. Another major barrier to efficiently launching ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... , ... Beddit® has launched a new Android app for use ... a more intuitive SleepScore™ that rates sleep quality on a 100-point scale and makes ... by a proprietary algorithm. Beddit analyzes the data to provide an easy to understand ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... provide scholarships for people struggling with eating disorders as a result of the ... second annual event, held at Fox Run Golf Club in Eureka, will help ...
(Date:11/25/2015)... ... 2015 , ... Many people know of the common symptoms of low thyroid ... skin. But many people who find their cholesterol levels and weight are creeping up ... especially if they don’t have any of the other symptoms. , Thyroid hormone plays ...
(Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
(Date:11/24/2015)... Dallas, Texas (PRWEB) , ... November 24, 2015 , ... ... of all charitable donations are made in the last five weeks of the year ... #GivingTuesday was created in 2012 to connect the nation’s charities with those individuals who ...
Breaking Medicine News(10 mins):